Association of Electrocardiogram Findings With Clinical Outcomes in Patients With Chronic Coronary Syndrome: An Analysis of the ISCHEMIA Trials - 18/12/24
Abstract |
Objective |
We aimed to investigate the association of electrocardiogram (ECG) findings with outcomes in patients with chronic coronary syndrome.
Methods |
This secondary analysis of the ISCHEMIA and ISCHEMIA-CKD trials divided patients with chronic coronary syndrome into two groups, those with a normal ECG tracing and abnormal ECG tracing. Repolarization abnormalities included ST-segment depression ≥ 0.5 mm and T-wave inversion ≥ 1 mm; conduction abnormalities included left and right bundle branch block (LBBB and RBBB). The primary endpoint was cardiovascular death. Outcomes were assessed using a covariate-adjusted Cox-regression model.
Results |
Of 5876 patients, 2901 (49.4%) had a normal and 2975 (50.6%) an abnormal ECG tracing. An abnormal ECG tracing at baseline, compared with a normal ECG tracing, was associated with an increased risk of cardiovascular death (257 of 2975 [8.6%] vs. 97 of 2901 [3.3%], adjusted hazard ratio [aHR] 2.01, 95% CI 1.58-2.55) over a median follow-up period of 3.1 years (IQR 2.1-4.2). This finding was consistent across subgroups except for patients with black skin color and current smokers, in whom an abnormal ECG was not significantly associated with increased risk of cardiovascular death. Individual ECG abnormalities (ST-segment depression [aHR 2.0, 95% CI 1.52-2.63], T-wave inversion [aHR 1.89, 95% CI 1.40-2.54], LBBB [aHR 1.74, 95% CI 1.05-2.90], and RBBB [aHR 1.52, 95% CI 1.04-2.22]) were independently associated with an increased risk of cardiovascular death.
Conclusion |
In patients with chronic coronary syndrome, an abnormal ECG tracing was associated with an increased risk of cardiovascular death. Our findings underscore the importance of the ECG in cardiovascular risk stratification and prognostication.
Trial Registration |
NCT01471522, BioLINCC ID 14539.
Le texte complet de cet article est disponible en PDF.Keywords : Cardiovascular events, Electrophysiology, Myocardial infarction, Stable coronary artery disease, Stenosis
Plan
| Funding: The ISCHEMIA and ISCHEMIA-CKD trials were sponsored by the National Heart, Lung, and Blood Institute and received additional support from Abbott, Abbott Vascular, Abbott (previously St. Jude Medical), Amgen, Arbor Pharmaceuticals, AstraZeneca, Espero Pharmaceuticals, Medtronic, Merck & Co., Omron, Philips (previously Volcano Corporation) and Sunovion Pharmaceuticals. No financial support was received for the conduct of this secondary analysis. |
|
| Conflict of Interest: No author reports conflict of interests relevant to this work. |
|
| Authorship: AJ and GG conceived the study idea. AJ and GG requested permission for use of the data from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center. AJ performed the statistical analysis and drew figures and tables. AJ and GG analyzed the data and drafted the manuscript. All authors critically revised the manuscript and approved the final version for publication. |
Vol 138 - N° 1
P. 61 - janvier 2025 Retour au numéro
Article précédent
- Heart Failure Mortality in Chronic Kidney Disease: The Fatal Crossover
- Yong-Hao Yeo, Boon-Jian San, Xuan-Ci Mee, Min Choon Tan, Amr E. Abbas, Madhan Shanmugasundaram, Justin Z. Lee, Aiden Abidov, Kwan S. Lee
- Effectiveness of Audit and Feedback and Academic Detailing Interventions to Support Safer Opioid Prescribing in Primary Care
- Meagan Lacroix, Fred Abdelmalek, Karl Everett, Monica Taljaard, Lena Salach, Lindsay Bevan, Victoria Burton, Hui Jia, Jennifer Shuldiner, Celia Laur, Emily Nicholas Angl, Noah M. Ivers, Mina Tadrous
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?